Lusinchi A, Mazeron J J, Martin M, Calitchi E, Langlois D, Lelièvre G, Peynègre R, Pierquin B
Ann Otolaryngol Chir Cervicofac. 1984;101(4):293-7.
From July 1971 to August 1981, 31 selected patients with T1, T2 tumours of the Tonsillar region were treated according to the following protocol: Telecobalt therapy to the primary site and to neck nodes to a dose of 45 Gy, Brachytherapy to the primary site to a dose of 25-30 Gy using iridium 192, Boost dose to involved neck nodes, with electrons, or radical neck dissection, wether N1, N2 or N3. The actuarial survival free of disease is 76% for the whole group and 86% for the NO group. The local control rate is 100% without any recurrences at the primary site having been observed. Disease control in the neck is 94% overall and 100% for the NO group. The effects on salivary function were reduced in comparison with telecobalt therapy alone. These favourable results favour the use of this protocol for superficial, minimally infiltrating tumours less than 4 cm in diameter without obvious extension to the base of the tongue or retromolar trigone.
1971年7月至1981年8月，31例经挑选的扁桃体区T1、T2期肿瘤患者按照以下方案进行治疗：对原发部位及颈部淋巴结进行远距离钴治疗，剂量为45 Gy；对原发部位使用铱192进行近距离治疗，剂量为25 - 30 Gy；对受累颈部淋巴结进行电子束推量照射或根治性颈清扫术，无论N1、N2还是N3期。全组无病精算生存率为76%，N0组为86%。局部控制率为100%，未观察到原发部位有任何复发。颈部疾病控制总体为94%，N0组为100%。与单纯远距离钴治疗相比，对唾液功能的影响有所减轻。这些良好结果支持将该方案用于直径小于4 cm、无明显向舌根或磨牙后三角区扩展的浅表、轻度浸润性肿瘤。
